0257 GMT - Ansell is likely to be the Australian healthcare stock that is most exposed to the impact of U.S. tariffs, Citi analysts write in a note. They acknowledge that breath-tech maker ResMed and medical-tech provider Nanosonics are probably impacted, given their manufacturing footprints, but not to the same extent as Ansell. The personal-protective equipment maker sources a majority of its products from Malaysia and Sri Lanka, both of which are among the countries hardest hit by tariffs, generating more than 40% of its revenue from the U.S. The exclusion of pharmaceuticals from tariffs is a relief for vaccine maker CSL, they add. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 03, 2025 22:57 ET (02:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.